Pramlintide Treatment Reduces 24-Hour Caloric Intake and Meal Sizes, and Improves Control of Eating in Obese Subjects: A 6-Week Translational Research Study Running Head: Effect of amylin agonism on human eating behavior

Evidence from rodent studies indicates that the -cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly-palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior, we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-hour caloric intake, portion sizes, “fast-food ” intake, and perceived control of eating in 88 obese subjects. After a 2-day placebo lead-in, subjects self-administered pramlintide (180 Cg) or placebo by subcutaneous injection 15 minutes before meals for 6 weeks, without concomitant lifestyle modifications. Compared to placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on Day 44 (-2.1 ± 0.3 % vs